MLXIPL and fatty liver disease: Thus TBE-31 suppresses liver steatosis, at least in part, by attenuating dietary stimulation of expression and activation of Srepb-1c, Chrebp, Lxrα, and Xbp1s, which consequently lowers expression of lipogenic enzymes.